12 hours ago
Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, the Fund appreciated 10.61% on an annualized basis, compared with 10.02% for the Benchmark and 14.83% for the Index. Strong stock selection in pharmaceuticals, biotechnology, health care equipment, and life sciences tools and services supported the Fund's outperformance, although limited exposure to managed care stocks reduced relative returns. The Fund remains positive on health care due to improving biotechnology funding, strong acquisition activity, recovering managed care margins, and growth from an aging population, chronic disease, medical innovation, and higher health care spending. In addition, please check the Fund's top five holdings to know the best picks in 2026.
In its second-quarter 2026 investor letter, Baron Health Care Fund highlighted Insmed Incorporated (NASDAQ:INSM). Insmed Incorporated (NASDAQ:INSM), which develops and commercializes therapies for patients with serious and rare diseases, detracted from the fund's performance during the quarter. On August 03, 2026, Insmed Incorporated (NASDAQ:INSM) closed at $98.45 per share. The one-month return of Insmed Incorporated (NASDAQ:INSM) was -12.56%, and its shares lost 11.59% over the past 52 weeks. Insmed Incorporated (NASDAQ:INSM) has a market capitalization of $21.34 billion.
Baron Health Care Fund stated the following regarding Insmed Incorporated (NASDAQ:INSM) in its Q2 2026 investor letter:
"Insmed Incorporated is a biotechnology company with three lead pulmonology ******* ets that we believe can collectively generate more than $8 billion in peak sales. We are particularly excited about Brinsupri for non-cystic fibrosis bronchiectasis, which we view as a $5 billion-plus opportunity. Despite what we believe has been a strong start to the launch, shares fell after first quarter Brinsupri sales missed expectations as investors focused on early signs of higher treatment discontinuations. Insmed's exit from the Nasdaq-100 Index created additional technical selling pressure. Long term, we continue to view Brinsupri as an important treatment option for the 500,000-plus bronchiectasis patients in the U.S. We remain bullish on the portfolio's long-term fundamentals, including the opportunity for treprostinil palmitil inhalation powder (TPIP), which is being studied for pulmonary arterial hypertension and pulmonary hypertension ******* ociated with interstitial lung disease. Compared to existing inhaled prostanoids that require four daily treatments, once-daily TPIP is more convenient and can be dosed at significantly higher levels, potentially resulting in meaningfully better efficacy."
#fund #baron
In its second-quarter 2026 investor letter, Baron Health Care Fund highlighted Insmed Incorporated (NASDAQ:INSM). Insmed Incorporated (NASDAQ:INSM), which develops and commercializes therapies for patients with serious and rare diseases, detracted from the fund's performance during the quarter. On August 03, 2026, Insmed Incorporated (NASDAQ:INSM) closed at $98.45 per share. The one-month return of Insmed Incorporated (NASDAQ:INSM) was -12.56%, and its shares lost 11.59% over the past 52 weeks. Insmed Incorporated (NASDAQ:INSM) has a market capitalization of $21.34 billion.
Baron Health Care Fund stated the following regarding Insmed Incorporated (NASDAQ:INSM) in its Q2 2026 investor letter:
"Insmed Incorporated is a biotechnology company with three lead pulmonology ******* ets that we believe can collectively generate more than $8 billion in peak sales. We are particularly excited about Brinsupri for non-cystic fibrosis bronchiectasis, which we view as a $5 billion-plus opportunity. Despite what we believe has been a strong start to the launch, shares fell after first quarter Brinsupri sales missed expectations as investors focused on early signs of higher treatment discontinuations. Insmed's exit from the Nasdaq-100 Index created additional technical selling pressure. Long term, we continue to view Brinsupri as an important treatment option for the 500,000-plus bronchiectasis patients in the U.S. We remain bullish on the portfolio's long-term fundamentals, including the opportunity for treprostinil palmitil inhalation powder (TPIP), which is being studied for pulmonary arterial hypertension and pulmonary hypertension ******* ociated with interstitial lung disease. Compared to existing inhaled prostanoids that require four daily treatments, once-daily TPIP is more convenient and can be dosed at significantly higher levels, potentially resulting in meaningfully better efficacy."
#fund #baron
1 day ago
Aug 3 (Reuters) - Vertex Pharmaceuticals on Monday raised the upper end of its annual revenue forecast, banking on robust demand for its cystic fibrosis treatments.
The company expects its annual revenue to be between $13.1 billion and $13.2 billion, compared with $12.95 billion to $13.1 billion previously. **** ysts on average expect 2026 revenue of $13.07 billion, according to data compiled by LSEG.
Vertex said its annual outlook excludes the pending Crinetics acquisition and that an updated forecast will be provided after the deal closes, which is expected in the third quarter.
Here are more details:
• Vertex's $10 billion acquisition of Crinetics expands its reach beyond cystic fibrosis, adding endocrine disorders to a diversification strategy that already includes povetacicept in kidney, Casgevy in sickle cell and Journavx in pain, **** ysts had said.
#cystic #fibrosis
The company expects its annual revenue to be between $13.1 billion and $13.2 billion, compared with $12.95 billion to $13.1 billion previously. **** ysts on average expect 2026 revenue of $13.07 billion, according to data compiled by LSEG.
Vertex said its annual outlook excludes the pending Crinetics acquisition and that an updated forecast will be provided after the deal closes, which is expected in the third quarter.
Here are more details:
• Vertex's $10 billion acquisition of Crinetics expands its reach beyond cystic fibrosis, adding endocrine disorders to a diversification strategy that already includes povetacicept in kidney, Casgevy in sickle cell and Journavx in pain, **** ysts had said.
#cystic #fibrosis
20 days ago
Palvella Therapeutics Inc. (NASDAQ:PVLA) is one of the 10 affordable biotech stocks to buy right now.
On June 29, Palvella Therapeutics Inc. (NASDAQ:PVLA) disclosed that it filed the initial module of its New Drug Application with the FDA for approval of QTORIN 3.9% rapamycin anhydrous gel. QTORIN is used to treat microcystic lymphatic malformations.
VILevi/Shutterstock.com
The company plans to file the remaining modules and conclude the NDA application process during the latter half of 2026. The company highlighted that QTORIN rapamycin has attained FDA designations for Orphan Drug, Fast Track designations, and Breakthrough Therapy. The company is also speeding up U.S. launch preparation for a possible independent commercial launch in the early half of 2027, subject to approval.
Earlier on June 22, the company revealed that the FDA had provided a rolling review for QTORIN rapamycin's New Drug Application. Palvella Founder and CEO, Wes Kaupinen, highlighted that the company plans to use the Breakthrough Therapy, the benefits of rolling review, and Fast Track designations to facilitate an efficient route toward achieving FDA approval. He further stated:
On June 29, Palvella Therapeutics Inc. (NASDAQ:PVLA) disclosed that it filed the initial module of its New Drug Application with the FDA for approval of QTORIN 3.9% rapamycin anhydrous gel. QTORIN is used to treat microcystic lymphatic malformations.
VILevi/Shutterstock.com
The company plans to file the remaining modules and conclude the NDA application process during the latter half of 2026. The company highlighted that QTORIN rapamycin has attained FDA designations for Orphan Drug, Fast Track designations, and Breakthrough Therapy. The company is also speeding up U.S. launch preparation for a possible independent commercial launch in the early half of 2027, subject to approval.
Earlier on June 22, the company revealed that the FDA had provided a rolling review for QTORIN rapamycin's New Drug Application. Palvella Founder and CEO, Wes Kaupinen, highlighted that the company plans to use the Breakthrough Therapy, the benefits of rolling review, and Fast Track designations to facilitate an efficient route toward achieving FDA approval. He further stated:
23 days ago
SOUTHPORT, England — David Howard was age 7 when he was diagnosed with cystic fibrosis. By the time he was a teenager — well before recent medical advances for this rare genetic condition — he’d found out via internet searches he wasn’t expected to live beyond his mid-20s.
Imagine, then, how blessed this Irishman, now 27, feels to be walking the sun-kissed fairways of Royal Birkdale and about to take on the best golfers in the world at the British Open.
“Here I am, as healthy as ever and playing at the Open. It’s just nuts,” Howard said with a smile at the back of the 18th green after his first practice round, in the company of former champions Padraig Harrington and Shane Lowry. “Yeah, I’d like to think I’m an inspiration.”
Being a qualified mechanic and No. 1,456 in the world amateur rankings ensures Howard, who came through one of four local qualifying events to take his place in golf’s oldest major, is no normal British Open participant.
Also making him different is what he packs in his golf bag for each round: As important as his clubs is his medication, with Howard taking up to 30 tablets a day to prevent infection and help digest food properly.
Imagine, then, how blessed this Irishman, now 27, feels to be walking the sun-kissed fairways of Royal Birkdale and about to take on the best golfers in the world at the British Open.
“Here I am, as healthy as ever and playing at the Open. It’s just nuts,” Howard said with a smile at the back of the 18th green after his first practice round, in the company of former champions Padraig Harrington and Shane Lowry. “Yeah, I’d like to think I’m an inspiration.”
Being a qualified mechanic and No. 1,456 in the world amateur rankings ensures Howard, who came through one of four local qualifying events to take his place in golf’s oldest major, is no normal British Open participant.
Also making him different is what he packs in his golf bag for each round: As important as his clubs is his medication, with Howard taking up to 30 tablets a day to prevent infection and help digest food properly.
23 days ago
Of the 156 players competing at this week's Open Championship, David Howard's journey to Royal Birkdale is among the most remarkable and inspiring.
For a long time, teeing it up at a major alongside the world's best golfers was nothing more than a pipe dream for the trained mechanic from county Cork.
When Howard was seven years old, he was diagnosed with cystic fibrosis, the genetic condition that causes sticky mucus to build up in the lungs and digestive system.
By his own estimate, Howard was in hospital "a few times a year" with infections.
"I remember when I first got access to a phone when I was 12, 13, I googled 'cystic fibrosis life expectancy' and it was saying mid-20s," the 27-year-old told BBC Sport NI's Stephen Watson.
For a long time, teeing it up at a major alongside the world's best golfers was nothing more than a pipe dream for the trained mechanic from county Cork.
When Howard was seven years old, he was diagnosed with cystic fibrosis, the genetic condition that causes sticky mucus to build up in the lungs and digestive system.
By his own estimate, Howard was in hospital "a few times a year" with infections.
"I remember when I first got access to a phone when I was 12, 13, I googled 'cystic fibrosis life expectancy' and it was saying mid-20s," the 27-year-old told BBC Sport NI's Stephen Watson.
1 month ago
Insmed Incorporated (NASDAQ:INSM) is one of the most promising healthcare stocks according to Wall Street ****** ysts. On June 10, Cantor Fitzgerald reaffirmed its Overweight rating on Insmed Incorporated (NASDAQ:INSM) and raised its price target from $230 to $235.
The firm pointed to an upcoming data release for Insmed's experimental lung drug TPIP as a potential catalyst that investors may be underestimating. TPIP, which stands for Treprostinil Palmitil Inhalation Powder, is an inhaled therapy Insmed is developing for pulmonary arterial hypertension (PAH).
According to Cantor Fitzgerald, it has been roughly a year since Insmed first presented the Phase 2b clinical trial results for TPIP in PAH. The firm sees the next data release as a moment that could meaningfully revive investor interest in the drug. This data is a one-year open label extension update expected in Q3 2026. For context, an open label extension is the phase of a clinical study where all patients are given the actual drug and monitored over a longer period, and the data from this phase typically gives a clearer picture of how durable and safe the treatment is over time.
The firm noted that if the next data release provides robust results, the market may shift focus from Brinsupri, Insmed's drug for non-cystic fibrosis bronchiectasis. This is because the market is significantly undervaluing TPIP just because Brinsupri posted blowout revenue at the end of Q1 2026.
Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company. It focuses on developing and commercializing therapies for serious and rare diseases. One of its lead approved product is ARIKAYCE, an inhaled antibiotic delivered via the Lamira Nebulizer System.
The firm pointed to an upcoming data release for Insmed's experimental lung drug TPIP as a potential catalyst that investors may be underestimating. TPIP, which stands for Treprostinil Palmitil Inhalation Powder, is an inhaled therapy Insmed is developing for pulmonary arterial hypertension (PAH).
According to Cantor Fitzgerald, it has been roughly a year since Insmed first presented the Phase 2b clinical trial results for TPIP in PAH. The firm sees the next data release as a moment that could meaningfully revive investor interest in the drug. This data is a one-year open label extension update expected in Q3 2026. For context, an open label extension is the phase of a clinical study where all patients are given the actual drug and monitored over a longer period, and the data from this phase typically gives a clearer picture of how durable and safe the treatment is over time.
The firm noted that if the next data release provides robust results, the market may shift focus from Brinsupri, Insmed's drug for non-cystic fibrosis bronchiectasis. This is because the market is significantly undervaluing TPIP just because Brinsupri posted blowout revenue at the end of Q1 2026.
Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company. It focuses on developing and commercializing therapies for serious and rare diseases. One of its lead approved product is ARIKAYCE, an inhaled antibiotic delivered via the Lamira Nebulizer System.
